DNTH
Dianthus Therapeutics, Inc.
$76.78
-1.75
(-2.23%)
Mkt Cap
4.29B
Volume
379,230
52W Range
32.28-117.88
Sector
Healthcare
Beta
0.08
EPS (TTM)
-0.13 USD
P/E Ratio
-9.81
Revenue (TTM)
1.90M USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (162.34M) | (84.97M) | (43.55M) | (28.48M) | (13.11M) | (74.94M) | (76.77M) | (57.52M) | (35.49M) | (9.43M) |
| EPS | -4.20 | -2.55 | -8.45 | -7.60 | -3.82 | -27.30 | -33.18 | -27.62 | -16.05 | -4.27 |
| Free Cash Flow | (129.27M) | (78.28M) | (36.97M) | (29.21M) | (60.80M) | (64.42M) | (60.16M) | (49.56M) | (24.46M) | (6.67M) |
| FCF / Share | -3.42 | -2.35 | -7.17 | -7.79 | -17.70 | -23.47 | -26.01 | -23.80 | -11.07 | -3.02 |
| Operating CF | (129.06M) | (78.18M) | (36.86M) | (29.07M) | (59.53M) | (64.02M) | (57.10M) | (41.89M) | (22.26M) | (6.53M) |
| Total Assets | 530.92M | 374.01M | 179.41M | 83.11M | 189.93M | 161.62M | 161.51M | 157.31M | 54.46M | 11.34M |
| Total Debt | 1.39M | 1.49M | 585,000 | 788,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 51.09M | 22.79M | 132.32M | 15.37M | 131.65M | 58.15M | 65.07M | 58.34M | 51.57M | 4.54M |
| Book Value | 493.40M | 352.48M | 168.87M | 73.66M | 172.67M | 143.91M | 141.19M | 145.65M | 50.32M | 9.04M |
| Return on Equity | -0.33 | -0.24 | -0.26 | -0.39 | -0.08 | -0.52 | -0.54 | -0.39 | -0.71 | -1.04 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 761,000 | 463,000 | 284,000 | 396,000 | 193,000 | 1.16M | 1.33M | 2.17M | 1.86M | 874,000 | 457,000 | 924,000 |
| Net Income | (50.22M) | (40.83M) | 97.91M | (36.77M) | (31.63M) | (29.51M) | (28.44M) | (25.17M) | (17.61M) | (13.75M) | (10.56M) | (14.76M) |
| EPS | -0.90 | -0.85 | 2.59 | -0.97 | -0.88 | -0.82 | -0.81 | -0.74 | -0.51 | -0.54 | -2.33 | -3.78 |
| Free Cash Flow | (49.16M) | (28.87M) | (47.12M) | (30.56M) | (23.94M) | (27.65M) | (27.48M) | (21.29M) | (14.54M) | (14.97M) | (11.86M) | 1.64M |
| FCF / Share | -0.88 | -0.60 | -1.25 | -0.81 | -0.67 | -0.77 | -0.78 | -0.62 | -0.42 | -0.58 | -2.62 | 0.42 |
| Operating CF | (48.98M) | (28.86M) | (46.98M) | (30.55M) | (23.89M) | (27.63M) | (27.44M) | (21.27M) | (14.53M) | (14.94M) | (11.85M) | 1.50M |
| Total Assets | 1.21B | 1.25B | 530.92M | 577.45M | 326.08M | 348.58M | 374.01M | 354.25M | 368.96M | 382.46M | 179.41M | 192.46M |
| Total Debt | 1.29M | 1.36M | 1.39M | 1.28M | 1.33M | 1.40M | 1.49M | 311,000 | 407,000 | 497,000 | 585,000 | 670,000 |
| Cash & Equiv | 110.55M | 627.67M | 51.09M | 55.98M | 13.24M | 10.12M | 22.79M | 33.67M | 314.17M | 329.72M | 132.32M | 157.28M |
| Book Value | 1.17B | 1.20B | 493.40M | 546.45M | 303.08M | 328.61M | 352.48M | 337.90M | 358.22M | 372.69M | 168.87M | 178.38M |
| Return on Equity | -0.04 | -0.03 | 0.20 | -0.07 | -0.10 | -0.09 | -0.08 | -0.07 | -0.05 | -0.04 | -0.06 | -0.08 |
DNTH News
Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics to Participate in Three Investor Conferences During September
Alyeska Investment Group L.P. Has $14.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH